Non-Alcoholic Steatohepatitis (NASH) Market Report by Manufacturers Like Allergan Plc. (Tobira Therapeutics), Cadila Healthcare Limited, Conatus Pharmaceuticals Inc.
The global non-alcoholic steatohepatitis (NASH) market generated $1,179 million in 2017, and is projected to reach $21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025.
View full press release